Álvaro A Cruz1, Sara Barile2, Elena Nudo2, Laura Brogelli3, Patricia Guller2, Alberto Papi4. 1. Fundação ProAR and Federal University of Bahia, Salvador, Brazil. cruz.proar@gmail.com. 2. Chiesi Farmaceutici SpA, Parma, Italy. 3. Polistudium srl, Milan, Italy. 4. University of Ferrara, Ferrara, Italy.
Abstract
BACKGROUND: The treatment with short-acting beta-2 agonists (SABA) alone is no longer recommended due to safety issues. Instead, the current Global Initiative for Asthma (GINA) Report recommends the use of the combination of inhaled corticosteroids (ICS) with the rapid/long-acting beta-2 agonist formoterol, although the use in steps 1 and 2 is still off-label in the EU and in many countries. It is important to understand clinicians' knowledge and opinions on the issue with the ultimate goal to encourage the implementation of the new approach in clinical practice. METHODS: We performed an international survey, directed to pulmonologists interested in the management of patients with asthma. RESULTS: Most participants reported that SABA alone should not be used in GINA Step 1 asthma treatment. As-needed low-dose ICS/formoterol combination to patients in step 1, and as-needed low-dose ICS/formoterol as reliever therapy in any step were found to be of current use prescribed in their real-life settings. SABA alone was still prescribed to a proportion of patients, although the pulmonologists' opinion was that it should no longer be used. CONCLUSIONS: Most specialists are up to date and understand the relevance of the changes in GINA reports from 2019. Nevertheless, dissemination and implementation of GINA novel management strategy is still needed.
BACKGROUND: The treatment with short-acting beta-2 agonists (SABA) alone is no longer recommended due to safety issues. Instead, the current Global Initiative for Asthma (GINA) Report recommends the use of the combination of inhaled corticosteroids (ICS) with the rapid/long-acting beta-2 agonist formoterol, although the use in steps 1 and 2 is still off-label in the EU and in many countries. It is important to understand clinicians' knowledge and opinions on the issue with the ultimate goal to encourage the implementation of the new approach in clinical practice. METHODS: We performed an international survey, directed to pulmonologists interested in the management of patients with asthma. RESULTS: Most participants reported that SABA alone should not be used in GINA Step 1 asthma treatment. As-needed low-dose ICS/formoterol combination to patients in step 1, and as-needed low-dose ICS/formoterolas reliever therapy in any step were found to be of current use prescribed in their real-life settings. SABA alone was still prescribed to a proportion of patients, although the pulmonologists' opinion was that it should no longer be used. CONCLUSIONS: Most specialists are up to date and understand the relevance of the changes in GINA reports from 2019. Nevertheless, dissemination and implementation of GINA novel management strategy is still needed.
Authors: Helen K Reddel; J Mark FitzGerald; Eric D Bateman; Leonard B Bacharier; Allan Becker; Guy Brusselle; Roland Buhl; Alvaro A Cruz; Louise Fleming; Hiromasa Inoue; Fanny Wai-San Ko; Jerry A Krishnan; Mark L Levy; Jiangtao Lin; Søren E Pedersen; Aziz Sheikh; Arzu Yorgancioglu; Louis-Philippe Boulet Journal: Eur Respir J Date: 2019-06-27 Impact factor: 16.671
Authors: Richard Beasley; Mark Holliday; Helen K Reddel; Irene Braithwaite; Stefan Ebmeier; Robert J Hancox; Tim Harrison; Claire Houghton; Karen Oldfield; Alberto Papi; Ian D Pavord; Mathew Williams; Mark Weatherall Journal: N Engl J Med Date: 2019-05-19 Impact factor: 91.245
Authors: R E Aldridge; R J Hancox; D Robin Taylor; J O Cowan; M C Winn; C M Frampton; G I Town Journal: Am J Respir Crit Care Med Date: 2000-05 Impact factor: 21.405
Authors: Michelle M Cloutier; Lara J Akinbami; Paivi M Salo; Michael Schatz; Tregony Simoneau; Jesse C Wilkerson; Gregory Diette; Kurtis S Elward; Anne Fuhlbrigge; Jacek M Mazurek; Lydia Feinstein; Sonja Williams; Darryl C Zeldin Journal: J Allergy Clin Immunol Pract Date: 2020-04-25
Authors: Jo Hardy; Christina Baggott; James Fingleton; Helen K Reddel; Robert J Hancox; Matire Harwood; Andrew Corin; Jenny Sparks; Daniela Hall; Doñah Sabbagh; Saras Mane; Alexandra Vohlidkova; John Martindale; Mathew Williams; Philippa Shirtcliffe; Mark Holliday; Mark Weatherall; Richard Beasley Journal: Lancet Date: 2019-08-23 Impact factor: 79.321
Authors: S Suissa; P Ernst; J F Boivin; R I Horwitz; B Habbick; D Cockroft; L Blais; M McNutt; A S Buist; W O Spitzer Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405